Trial Profile
Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate Treatment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 11 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov. (parent trial: NCT01253265)
- 11 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (parent trial: NCT01253265)
- 04 Aug 2011 Status of parent trial changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.